Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beremagene geperpavec - Krystal Biotech

Next Previous
Drug Profile

Beremagene geperpavec - Krystal Biotech

Alternative Names: B-VEC; Bercolagene telserpavec; Beremagene geperpavec-svdt; HSV1-COL7; KB-103; KB-803; VYJUVEK

Latest Information Update: 14 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action COL7A1 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa dystrophica
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epidermolysis bullosa dystrophica

Most Recent Events

  • 15 May 2026 Registered for Epidermolysis bullosa dystrophica in United Kingdom (Topical)
  • 04 May 2026 Krystal Biotech completes enrolment in the phase III IOLITE trial for Epidermolysis bullosa dystrophica (In infants, In the elderly, In children, In adults, In adolescents) in USA (Ophthalmic) (NCT07016750)
  • 19 Feb 2026 Beremagene geperpavec is covered by patent protection in Japan, Australia, New Zealand, Chile, India, Mexico and Singapore

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top